Dihydrocodeine

Summary

Dihydrocodeine (CHEMBL1595) is an approved small molecule (ATC N02AA08); indicated across 1 condition.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: N02AA08 (+1 more)
• Indications: 1 condition
• Clinical trials: 1
• Chemistry: 301.4 Da · C18H23NO3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1595
Name	Dihydrocodeine
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	5284543
ATC	N02AA08, N02AA58
Molecular formula	C18H23NO3
Molecular weight	301.4
InChIKey	RBOXVHNMENFORY-DNJOTXNNSA-N

SMILES: CN1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)OC)O[C@H]3[C@H](CC4)O

IUPAC name: (4R,4aR,7S,7aR,12bS)-9-methoxy-3-methyl-2,4,4a,5,6,7,7a,13-octahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-ol

Also known as: .alpha.-hydrocodol, Codhydrine, Dehacodin, Dh-codeine, Dihidrocodeina, Dihydrocodeine, IDS-ND-008(SECT.2), Novicondin, NSC-231319, Rapacodin, Remedacen, DIHYDROCODEINE

Parent form; salt/anhydrous children: CHEMBL2062266

Patent coverage: 4,418 distinct patent families (18,328 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 18,313 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication record carries no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
PHASE4	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00547885	PHASE4	COMPLETED	Randomized Controlled Double Blind Trial of Short vs Long Acting Dihydrocodeine in Chronic Non-malignant Pain

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline, but PharmGKB curates 1 clinical and 9 variant annotation(s) for this drug (gene-keyed; see PharmGKB).

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).